U.S. Markets close in 4 hrs 12 mins
Stocks To Watch

Target soars on sales rebound, Urban Outfitters surges on beat, Apple eyes Hollywood

Shire plc (SHPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
148.07+0.36 (+0.24%)
As of 11:48AM EDT. Market open.
People also watch
ALXNJAZZBMRNBAXREGN
Full screen
Previous Close147.71
Open148.91
Bid148.59 x 200
Ask148.65 x 300
Day's Range148.06 - 149.73
52 Week Range147.28 - 209.22
Volume1,160,155
Avg. Volume1,329,889
Market Cap44.8B
Beta1.65
PE Ratio (TTM)151.87
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.92 (0.63%)
Ex-Dividend Date2017-03-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journalsyesterday

    Shire applies for European approval of potential blockbuster eye drop

    One of the state’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016. It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by Allergan plc (AGN) that’s approved to increase tear production due to inflammation.

  • TheStreet.comyesterday

    Shire Gains as it Seeks European Approval For Dry Eye Treatment

    The drug would be the first such treatment in Europe.

  • Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
    Zacks12 days ago

    Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

    Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.